Clinical Trial Update: A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR [Phase 3]

View source ↗

Summary

This clinical trial update reports a multicenter Phase III randomized study comparing second-line chemotherapy with or without erlotinib in NSCLC patients with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Centre Francois Baclesse | Conditions: NSCLC Patients With EGFR Activating Mutation | Phase 3 | Status: TERMINATED